Tang L, Hijano DR, Gaur AH, et al. - Based on reported 94.8% efficacy, a 2-dose regimen of the BNT162b2 vaccine (Pfizer-BioNTech) against SARS-CoV-2 was authorized in December 2020. The relationship between vaccination and a reduction with asymptomatic infection remains unclear, although an association with symptomatic disease has been well described.